Why Moderna Shares Rose 33.7% in May
Shares of Moderna (NASDAQ: MRNA) climbed 33.7% in May, according to data provided by S&P Global Market Intelligence, after the company reported encouraging data from its investigational coronavirus vaccine's phase 1 trial. Across all participants in two dosage groups, Moderna said, levels of binding antibodies were at or above levels seen in people who have recovered from the virus. Information on neutralizing antibodies (those that block infection) were only available for eight people.
